Discover an informative webinar featuring leading researchers as they discuss advancements in biomarker discovery for Alzheimer’s disease (AD) and related dementias.
The expert speakers will present on the validation and application of a highly sensitive and low-volume multiplexed assay designed to detect key neurodegenerative disease biomarkers. They will explore how this platform enhances the measurement of critical Alzheimer’s biomarkers, such as pTau217, offering a minimally invasive and scalable approach for early diagnosis and disease monitoring in both sporadic and autosomal dominant AD.
They will follow with a discussion on large-scale plasma proteomics and its role in identifying disease-specific biomarkers across neurodegenerative diseases, including AD, Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). Her research highlights the power of plasma pTau217 as a predictive biomarker for amyloid pathology and the broader impact of proteomic profiling in precision medicine.
This webinar will showcase how the multiplexed assay is setting a new benchmark for biomarker research, enabling high-sensitivity, low-volume detection to transform Alzheimer’s and dementia diagnostics, research and clinical applications.
Register for this webinar to gain insights into highly sensitive multiplexed assay and plasma proteomics for neurodegenerative disease diagnostics.
reas, CNS, Alzheimer’s Disease Trials, Translational Research, AD
Go to Event Website Advertisements